Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model

Clinical Microbiology and Infection

Volumn 13, Issue 2, 2007, Pages 202-205

  Daikos, G L ^a   Panagiotakopoulou, A ^a   Tzelepi, E ^b   Loli, A ^b   Tzouvelekis, L S ^a   Miriagou, V ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Animal model; Imipenem; Klebsiella pneumoniae; Metallo lactamases; Thigh infection model; VIM 1

Indexed keywords

AZTREONAM; CEFTAZIDIME; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROBACTER INFECTION; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRAIN DIFFERENCE; THIGH; WILD TYPE;

ANIMALIA; BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE; MURINAE; MUS;

EID: 33846296202     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01590.x     Document Type: Article

References (11)

1. Giakkoupi P, Xanthaki A, Kanelopoulou M et al. VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003; 41: 3893-3896.
2. Ikonomidis A, Tokatlidou D, Kristo I et al. Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-β-lactamase gene. J Clin Microbiol 2005; 43: 5344-5347.
3. Walsh TR, Toleman MA, Poirel L et al. Metallo-β-lactamases: The quiet before the storm? Clin Microbiol Rev 2005; 18: 306-325.
4. Giakkoupi P, Tzouvelekis LS, Daikos GL et al. Discrepancies and interpretation problems in susceptibility testing of VIM-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2005; 43: 494-496.
5. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-292.
6. Anhalt JP. Assays for antimicrobial agents in body fluids. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ, eds, Manual of clinical microbiology, 4th edn. Washington, DC: American Society for Microbiology, 1985; 1009-1014.
7. Fantin B, Leggett J, Ebert S et al. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 1991; 35: 1413-1422.
8. Fluckiger U, Segessenmann C, Gerber AU. Integration of pharmacokinetics and pharmocodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother 1991; 35: 1905-1910.
9. Takata T, Aizawa K, Shimizu A et al. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother 2004; 10: 76-85.
10. Drussano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36(suppl 1): 42-50.
11. Bellais S, Mimoz O, Leotard S et al. Efficacy of β-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-β-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2032-2034.